Pixium Vision

Share Issue/Capital Change • Jul 17, 2014

Pixium Vision implements a liquidity agreement with Gilbert Dupont

Paris, France. July 17 th , 2014. 7:30 CET – Pixium Vision (FR0011950641 – PIX eligible to PEA-PME), a company developing innovative Vision Restoration Systems (VRS) to allow patients who have lost their sight lead more independent lives, announced that it has entrusted Gilbert Dupont with the implementation of a liquidity agreement for a 12 month period, renewable by tacit agreement, on Pixium Vision shares traded on Euronext Paris (Compartment C). The agreement is effective on July 18th , 2014.

This agreement is in accordance with the Charter of Ethics established by the AMAFI of March 8, 2011 and approved by the decision of the Autorité des Marchés Financiers of 21 March 2011. €300 000 (three hundred thousand euros) have been allocated for the implementation of this liquidity contract.

Contacts

Pixium Vision Pierre Kemula, CFO contact@pixium-vision.com +33 1 76 21 47 30

Investors Relations / Press Relations Citigate Dewe Rogerson Lucie Larguier – Laurence Bault (Paris) Mark Swallow – David Dible (Londres) pixium-vision@citigate.fr / pixium-vision@citigatedr.co.uk +33 1 53 32 84 78 / +44 20 7282 2948

About Pixium Vision (www.pixium-vision.com)

Pixium Vision is developing innovative Vision Restoration Systems (VRS) that aim to significantly improve the independence, mobility and quality of life of patients who have lost their sight. The Company intends to harness the rapid advances being made in visual processing, microelectronics, optoelectronics, and intelligent software algorithms to develop systems that for blind people could ultimately provide vision approaching that of a normal healthy eye.

Pixium Vision is developing two VRS platforms:

• IRIS® : Clinical trials are currently underway with IRIS® in several centers in Europe with the goal of applying for CE Mark. Commercialization of IRIS® is expected to begin in 2015, subject to the obtaining of the CE Mark. Pixium Vision will continue to improve the performance of the IRIS® VRS notably through the development of new algorithms and software.
• PRIMA: Currently in preclinical development. The Company plans to begin clinical trials of PRIMA in Europe in 2016.

Pixium Vision was created in 2011 in Paris as a result of combined research, by the Vision Institute, the Pierre et Marie Curie University (UPMC), as well as the collaborative work of several European and American teams from prestigious academic and technological institutions, including Stanford University (USA).

Pixium Vision is an ISO 13485 certified company. Pixium Vision is listed on Euronext (Compartment C) in Paris. ISIN: FR0011950641; ticker: PIX

IRIS® is a trademark of Pixium-Vision SA

For more information, please visit www.pixium-vision.com

Disclaimer:

This announcement does not, and shall not under any circumstances, constitute a public offering or an invitation to the public in connection with any offer of securities. The distribution of the announcement in certain countries may constitute a breach of applicable law. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.

In particular, this announcement is not an offer of securities in the United States. The securities to which these materials relate have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act. There will be no public offering of the securities in the United States.